SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

20 Jul 2022 Evaluate
The sales is pegged at Rs. 8568.98 millions for the June 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 11539.00 millions during the year-ago period.Net profit of the cmpany stood at Rs. 2294.54 millions for the quarter ended June 2022 a decline of -34.57% from Rs. 3506.75 millions  in the same quarter last year.The company reported a degrowth in operating Profit to 3445.95 millions from 4981.41 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 8568.98 11539.00 -25.74 8568.98 11539.00 -25.74 44007.08 34628.76 27.08
Other Income 743.92 618.40 20.30 743.92 618.40 20.30 2239.40 1347.76 66.16
PBIDT 3445.95 4981.41 -30.82 3445.95 4981.41 -30.82 17345.79 14370.43 20.70
Interest 9.00 10.01 -10.09 9.00 10.01 -10.09 52.40 34.11 53.62
PBDT 3436.95 4971.40 -30.87 3436.95 4971.40 -30.87 17293.39 14336.32 20.63
Depreciation 349.11 252.77 38.11 349.11 252.77 38.11 1102.96 987.80 11.66
PBT 3087.84 4718.63 -34.56 3087.84 4718.63 -34.56 16190.43 13348.52 21.29
TAX 793.30 1211.88 -34.54 793.30 1211.88 -34.54 4068.88 3378.47 20.44
Deferred Tax 38.90 -15.06 -358.30 38.90 -15.06 -358.30 140.08 1.20 11573.33
PAT 2294.54 3506.75 -34.57 2294.54 3506.75 -34.57 12121.55 9970.05 21.58
Equity 164.65 163.90 0.46 164.65 163.90 0.46 164.30 163.59 0.43
PBIDTM(%) 40.21 43.17 -6.85 40.21 43.17 -6.85 39.42 41.50 -5.02

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×